Analyst at Goldman Sachs Upgrades Myriad Genetics Stock and Raises Price Target
On January 30, 2024, Matthew Sykes, an analyst at Goldman Sachs, expressed his optimistic stance on the stock of Myriad ...
© 2024 Stocks Today
Tag: MYGN
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools
-
The Future of Secure Communications: How Quantum-Resistant Encryption is Revolutionizing Wireless Technology
-
The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions
-
Unlocking Potential: How Recent Acquisitions in the Battery Technology Sector Are Reshaping the Energy Landscape